This editorial refers to 'Prognostic impacts of Rho-kinase activity in circulating leucocytes in patients with vasospastic angina' † , by T. Nihei et al., on page 952.
Coronary vasospasm involves sudden, unexpected near obliteration of a native coronary artery, producing incapacitating chest pain and myocardial ischaemia. This disabling, and seemingly unresolved, vascular pathology can usually be treated medically, if correctly diagnosed, 1 although prognostic information is limited to risk scores derived from retrospective cohort studies. 2 However, its proper identification and diagnosis have, to date, remained elusive. Coronary vasospasm is particularly prevalent in Asian populations, with a potential recent slight upward trend in diagnosis. 3, 4 Rho-kinases work through GTP-binding protein in vascular smooth muscle cells (VSMCs) to reduce the bioavalability of nitric oxide (NO) and also enhance VSMC contraction and remodelling. 5 Rho-kinase A (RhoA) serves as a switch between an inactive GDPbound state and an active GTP-bound form that activates downstream targets. When triggered, RhoA induces VSMC contraction by increasing cytosolic Ca 2þ and Rho-kinase activity. Downstream targets of this activation include stimulating myosin light chain in VSMCs and endothelial NO synthase (eNOS) in endothelial cells, thus promoting enhanced vascular tone. Secondarily, reduced eNOS enhances the concentration and activity of reactive oxygen species, further degrading the ability of VSMCs to relax. Thus, Rho-kinase is a reasonable candidate to evaluate in the vascular pathobiology of coronary vasospasm.
In their unique investigation into vascular dysfunction of the coronary circulation in this issue of the journal, Nihei et al. provide some of the first insights into a novel way to evaluate and potentially ameliorate vasospastic angina (VSA). 6 Given that Rho-kinase levels and activity in circulating leucocytes are central mediators of coronary spasm, 5, 7, 8 the authors measured Rho-kinase activity in circulating leucocytes in patients with non-obstructive coronary artery disease (CAD) and assessed coronary vasospasm. VSA was defined by > 90% stenosis of the epicardial coronary artery along with ECG changes and/or symptoms and microvascular dysfunction, defined as an increase in lactate production without demonstrable epicardial stenosis, resulting from acetylcholine provocation testing. Of 233 patients, 178 had a positive acetylcholine provocation test (4 excluded in the final analysis) and 55 did not have VSA (5 excluded in the final analysis). Interestingly, only 7% of patients in the entire cohort of 768 patients did not have endothelial dysfunction-assuming those with obstructive CAD had concomitant endothelial dysfunction. Among baseline characteristics, only Rho-kinase activity in circulating leucocytes was found to be significantly higher in patients with VSA. When evaluated in a receiver operating characteristic (ROC) analysis, a median Rho-kinase activity, expressed as the ratio of phosphorylated myosin-binding subunit (p-MBS) to the total MBS (t-MBS), a value of 1.24 p-MBS/t-MBS was used to differentiate high from low Rho-kinase activity, with a sensitivity of 90% and specificity of 64%. Importantly, those with high Rho-kinase activity were found to be at greater risk of a cardiac event [predominantly hospitalization for unstable angina (UA)], whereas no events were observed in the non-VSA patients. Finally, when combined with the Japanese Coronary Spasm Association (JCSA) score, the prognostic impact in VSA patients significantly increased towards cardiac events. Seemingly a quick verification of the JCSA score 2 in Western populations would go a long way towards expanding the generalizability of this work. The authors observed an association between Rho-kinase activity and angina frequency, and, when added to nearly any metric, Rhokinase levels appeared to enhance the prediction of events in patients with VSA. Interestingly, the authors found no correlation between inflammatory markers and Rho-kinase activity, and presumably no difference in circulating leucocytes between the two groups. Although there appeared to be no inflammatory connection, Rho-kinase is well known to be a mediator in the inflammatory cascade, 9 has been associated with smoking, 10 and is reduced with statin use. 11 One potential explanation is the different mechanism underlying endothelial dysfunction and VSA. It could be postulated that inflammation may play a more significant role in the mechanism of endothelial dysfunction than in vascular spasm. However, work will be needed to elucidate the potential role, or lack thereof, of Rho-kinase in the inflammatory milieu of VSA. Specifically, it would be interesting to determine whether any inhibitors of Rho-kinase could be used as a potential therapy to ameliorate symptoms and improve coronary epicardial and/or microvascular blood flow in patients with VSA. One specific inhibitor of Rho-kinase ( SAR407899 12 ) has been found to reduce endothelial end-organ damage in the heart and kidneys of animal models of hypertension. 13 An ongoing clinical trial intends to test this hypothesis using SAR407899 in patients with microvascular angina and/or persistent angina despite angiographically successful elective percutaneous coronary intervention. 14 The findings of Nihei et al. are intriguing and potentially paradigm altering-particularly if the data can be extrapolated and confirmed in larger cohorts of the general population, including non-Asian patients. The conceivable implications for individualized diagnosis and treatment of VSA are exciting, and could change the existing clinical approach to patients with VSA ( Figure 1) . Currently, patients with non-obstructive disease are either treated empirically medically or undergo coronary physiology testing. 15 The patients are medically managed based on the results of the physiological assessment.
However, in a model using a more individualized and molecularly specific approach, one could envisage patients evaluated by undergoing both coronary physiology as well as biomarker testing, using assays such as Rho-kinase activity, to tailor the medical approach further, to treat symptoms, and improve coronary blood flow. Other potential targets for precision treatment may include C-reactive protein, which could be targeted with high-dose statins similar to the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study. 16 Furthermore, the inflammatory agent uric acid has recently been implicated in microvascular disease, 17 and administration of colchicine has been found to be beneficial at reducing plaque volume and high sensitivity C-reactive protein in patients with recent acute coronary syndromes. 18 Finally, with the recent Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial, 19 a renewed and undeniable link between CAD-both obstructive and non-obstructive-and the inflammatory cascade has refocused the field, and should drive the study of other inflammatory mediators and their association with CAD and/ or microvascular disease. Altogether, the results of this initial and preliminary study might not only be promising to those patients who suffer from VSA, but may also offer a potential game-changing approach to treating patients with non-obstructive CAD. Further confirmation of these data in larger populations, and potential exploration of other 
